SANA vs TENX: fair value comparison
Sana Biotechnology, Inc. and Tenax Therapeutics, Inc. · Updated 2026-10-19
SANA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. TENX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SANA currently ranks higher by quality score.
| SANA | TENX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $2.27 | $1.36 |
| 12-month range | $2.27–$5.59 | $1.36–$18.32 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #297 of 301 Healthcare | #298 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | — |
| Margin trend | — | Contracting |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: SANA fair value analysis · TENX fair value analysis